时辰化疗联合调强放疗治疗局部晚期鼻咽癌的随访结果分析
该随机对照研究将160例局部晚期鼻咽癌患者分为时辰组与常规组,均接受TPF方案诱导化疗后行IMRT同步顺铂化疗,中位随访31个月。结果显示两组1年、3年总生存、无进展生存、无局部复发生存及无远处转移生存率差异均无统计学意义,但时辰组听力损伤、吞咽困难和颈部纤维化发生率显著更低。
要点
- 时辰化疗联合IMRT未改善局部晚期鼻咽癌的远期生存。
- 时辰组听力损伤、吞咽困难和颈部纤维化发生率显著低于常规组。
- 时辰化疗可作为降低远期不良反应的化疗时序调整策略。
核心结论
- 与常规化疗联合IMRT相比,时辰化疗联合IMRT治疗局部晚期鼻咽癌不降低远期生存,但能降低不良反应发生率。
研究设计与样本
- 随机对照研究,采用随机数字表法将160例局部晚期鼻咽癌患者分为时辰组和常规组,每组80例。
- 两组均接受TPF方案(多西他赛+顺铂+氟尿嘧啶)诱导化疗2个周期,每周期21 d,诱导化疗结束3周后行IMRT同步顺铂方案化疗共3个周期。
- 同步放化疗结束后中位随访31个月,观察远期不良反应和生存情况。
主要发现
- 时辰组听力损伤发生率为22.72%,低于常规组的39.13%(P<0.05)。
- 时辰组吞咽困难发生率为0,低于常规组的8.69%(P<0.05)。
- 时辰组颈部皮肤纤维化发生率为4.54%,低于常规组的15.94%(P<0.05)。
- 两组1年总生存率分别为97.0%和92.8%,3年总生存率分别为80.3%和81.2%,差异无统计学意义(P>0.05)。
- 两组1年无进展生存率分别为95.5%和87.0%,3年无进展生存率分别为71.2%和73.9%,差异无统计学意义(P>0.05)。
关键数值与推荐
- 时辰组与常规组1年无局部复发生存率分别为97.0%和95.7%,3年无局部复发生存率分别为92.4%和92.8%,差异均无统计学意义(P>0.05)。
- 时辰组与常规组1年无远处转移生存率分别为97.0%和98.6%,3年无远处转移生存率分别为90.9%和91.3%,差异均无统计学意义(P>0.05)。
临床怎么用
- 对局部晚期鼻咽癌行诱导化疗联合IMRT同步化疗时,可考虑采用按时辰节律给药的化疗时序以降低听力损伤、吞咽困难和颈部纤维化风险。
- 时辰化疗未显示生存获益,选择该策略应以减少远期不良反应为主要目的。
局限性
- 中位随访仅31个月,长期生存与晚期不良反应数据有限。
- 研究仅报告单中心160例结果,外部推广需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the long-term effect and safety of chrono-chemotherapy combined with intensity modulated radiotherapy (IMRT) in locally advanced nasopharyngeal carcinoma (NPC). Methods: 160 patients with locally advanced NPC were randomly divided into a chrono group and conventional group according to random number table. In the first stage, all patients underwent two cycles of induced chemotherapy, consisting of docetaxel, cisplatin and 5-Fu every 21 days. Notably, patients received chrono-moduated chemotherapy according to circadian rhythm in the chrono group, and conventional chemotherapy in the conventional group. Then, 21 days after the completion of first stage, three cycles of concurrent cisplatin chemotherapy every 21 days were given to all patients during IMRT. The median follow-up after the completion of radiotherapy was 31 months. Long-term side effects and the survival of patients were observed. Results: Patients in the chrono group had significantly lower rates of hearing loss (22.72%), dysphagia (0) and neck fibrosis (4.54%) compared with those in the conventional group (39.13%、8.69%, 15.94%, respectively, all P<0.05). Meanwhile, the 1- year overall survival rates (97.0% vs 92.8%), 3-year overall survival rates (80.3% vs 81.2%), 1-year progression free survival rates (95.5% vs 87.0%), 3-year progression free survival rates (71.2% vs 73.9%), 1-year locoregional relapse-free survival rates (97.0% vs 95.7%), 1-year locoregional relapse-free survival rates (92.4% vs 92.8%), 1-year distant metastasis-free survival rates (97.0% vs 98.6%) and 3-year distant metastasis-free survival rates (90.9% vs 91.3%) between the chrono group and the conventional group were not statistically significant (all P>0.05). Conclusions: Compared with conventional chemotherapy, chrono-chemotherapy combined with IMRT didn't affect long-term survival, but reducing the incidence of adverse events in patients with locally advanced NPC. 目的: 评价时辰化疗联合调强放疗治疗局部晚期鼻咽癌的远期疗效和安全性。 方法: 采用随机数字表法,将160例局部晚期鼻咽癌患者随机分为时辰组和常规组,每组80例。时辰组采用TPF方案[多西他赛+顺铂(DDP)+氟尿嘧啶]时辰诱导化疗2个周期,每周期21 d。诱导化疗结束3周后,行调强放疗(IMRT)同步DDP方案化疗。化疗从放疗的第1天开始,每周期21 d,直到放疗结束,共3个周期。常规组常规行TPF方案诱导化疗和IMRT同步DDP方案化疗。同步放化疗结束后,中位随访31个月,观察远期不良反应和患者生存情况。 结果: 时辰组听力损伤、吞咽困难和颈部皮肤纤维化的发生率分别为22.72%、0和4.54%,均明显低于常规组(分别为39.13%、8.69%和15.94%,均P<0.05)。时辰组和常规组患者的1年总生存率分别为97.0%和92.8%,3年总生存率分别为80.3%和81.2%;1年无进展生存率分别为95.5%和87.0%,3年无进展生存率分别为71.2%和73.9%;1年无局部复发生存率分别为97.0%和95.7%,3年无局部复发生存率分别为92.4%和92.8%;1年无远处转移生存率分别为97.0%和98.6%,3年无远处转移生存率分别为90.9%和91.3%,差异均无统计学意义(均P>0.05)。 结论: 与常规化疗联合IMRT相比,时辰化疗联合IMRT治疗局部晚期鼻咽癌并不降低患者的远期生存,但能降低不良反应的发生率。.
引用
- Liu KQ, Jin F, Jiang H, et al. [Analysis of follow-up results of chrono-chemotherapy or conventional chemotherapy combined with intensity modulated radiotherapy in locally advanced nasopharyngeal carcinoma]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32135648. doi:10.3760/cma.j.issn.0253-3766.2020.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。